The FDA granted emergency use authorization to Quidel for the company’s Lyra SARS-CoV-2 assay, a real-time test designed to detect the COVID-19 nucleic acid in nasopharyngeal or oropharyngeal swab specimens from potentially infected patients.
“Emergency Use Authorization for our Lyra SARS-CoV-2 Assay allows Quidel to join the global fight against the COVID-19 outbreak by providing health care workers in highly complex laboratories with a fast, accurate tool to diagnose patients infected with the novel coronavirus,” Douglas Bryant, president and CEO of Quidel, said in a
Uncategorized